This application claims the benefit of U.S Provisional Application No. 60/051,739 filed Jul. 3, 1997.
Entry |
---|
Fakharzadeh et al., Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line, The EMBO Journal 10(6), 1565-1569 (1991). |
Bank et al., Enhanced binding of a 95 kDa protein to p53 cells undergoing p54-mediated growth arrest, The EMBO Journal 11(6), 2115-2121 (1992). |
Dubs-Poterszman et al., MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest, Oncogene 11, 2445-2449 (1995). |
Momand et al., The mdm-2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation, Cell 69, 1237-1245 (1992). |
Sigalas et al., Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer, Nature Medicine, 2(8), 912-917 (1996). |
Jones et al., Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53, Nature 378, 206-208 (1995). |
Montes de Oca Luna et al., Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53, Nature 378, 203-206 (1995). |
Oliner et al., Amplification of a gene encoding a p53-associated protein in human sarcomas, Nature 358, 80-83 (1992). |
Oliner et al. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53, Nature 362, 857-860 (1993). |
Fiddler et al., Amplification of MDM2 Inhibits MyoD-Mediated Myogenesis, Molecular & Cellular Biology 16(9), 5048-5057 (1996). |
Finlay, The mdm-2 Oncogene Can Overcome Wild-Type p53 and mdm2 Proteins, Molecular & Cellular Biology, 13(1), 301-306 (1993). |
Haines et al., Physical & Functional Interaction between Wild-Type p53 and mdm2 Proteins, Molecular & Cellular Biology 14(2), 1171-1178 (1994). |
Chen et al., mdm-2 Inhibits the G1 Arrest and Apoptosis Functions of the p53 Tumor Suppressor Protein, Molecular & Cellular Biology 16(5), 2445-2452 (1996). |
Chen et al., Mapping of the p53 and mdm-2 Interaction Domains, Molecular & Cellular Biology 13(7), 4107-4114 (1993). |
Haupt et al., Cell type-spcific inhibition of p53-mediated apoptosis by mdm2, The EMBO Journal 15(7), 1596-1606 (1996). |
Leach et al. p53 Mutation and MDM2 Amplification in Human Soft Tissue Sarcomas, Cancer Research 53, 2231-2234 (1993). |
Cordon-Cardo et al., Molecular Abnormalities of mdm2 and p53 Genes in Adult Soft Tissue Sarcomas, Cancer Research 54, 794-799 (1994). |
Wu et al., The p53-mdm-2 autoregulatory feedback loop, Genes & Development 7, 1126-1132 (1993). |
Cahilly-Snyder et al., Molecular Analysis and Chromosomal Mapping of Amplified Genes Isolated from a Transformed Mouse 3T3 Cell Line, Somatic Cell & Molecular Genetics 13(3) 235-244 (1987). |
Epstein, The genetics of human skin diseases, Current Opinion in Genetics & Development 6, 295-300 (1996). |
Williams, Ichthyosis: Mechanisms of Disease, Pediatric Dermatology 999(4), 365-368 (1992). |
Wall, RJ Transgenic Livestock: Progress and prospects for the future. Theriogenology 45: 57-68, 1996. |
Mullins et al. Fulminant hyoertension in transgenic rats harboring the mouse Ren-2 gene. Nature 344: 541-544, Apr. 1990. |
Hammer et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human b2m: An animal model of HLA-B27-associated disorders. Cell 63: 1099-1112, Nov. 1990. |
Mullins et al. Expression of the DBA/2J ren-2 gene in the adrenal gland of transgenic mice. EMBO J. 8: 4065-4072, 1989. |
Taurog et al. HLA-B27 in inbred and non-inbred transgenic mice. J. Immunol. 141: 4020-4023, Dec. 1988. |
Lundgren et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes and Devlopment 11(6): 714-725, Mar. 1997. |